Nitroreductase: A prodrug-activating enzyme for cancer gene therapy

被引:105
|
作者
Searle, PF [1 ]
Chen, MJ
Hu, LQ
Race, PR
Lovering, AL
Grove, JI
Guise, C
Jaberipour, M
James, ND
Mautner, V
Young, LS
Kerr, DJ
Mountain, A
White, SA
Hyde, EI
机构
[1] Univ Birmingham, Canc Res UK Inst Canc Studies, Birmingham B15 2TT, W Midlands, England
[2] Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England
[3] Keele Univ, ML Res, Keele, Staffs, England
[4] Rutgers State Univ, Dept Pharmaceut Chem, Ernest Mario Sch Pharm, Piscataway, NJ USA
关键词
adenovirus; bacteriophage lambda; cancer; CB1954; clinical trial; Escherichia coli; gene therapy; nitroreductase; oncolytic viruses; prodrug; protein engineering;
D O I
10.1111/j.1440-1681.2004.04085.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
1. The prodrug CB1954 (5-(aziridin-1-yl)-2,4-dinitrobenzamide) is activated by Escherichia coli nitroreductase (NTR) to a potent DNA-crosslinking agent. 2. Virus-mediated expression of NTR in tumour cells sensitizes them to CB1954 in vitro and in vivo, providing the basis for a strategy of cancer gene therapy. 3. A phase I trial of CB1954 in cancer patients has been completed, documenting the pharmacokinetics and establishing an acceptable dose. Subsequent trials of the replication-defective adenovirus CTL102 in patients with resectable tumours have documented expression of NTR in injected colorectal liver metastases, hepatocellular carcinoma, head and neck cancer and prostate cancer. Trials combining CTL102 and CB1954 are underway. 4. An oncolytic (replication-competent) adenovirus vector allowed increased expression of NTR in vitro and in a mouse tumour model, resulting in a greater reduction in tumour growth when combined with CB1954 treatment. 5. Alternative prodrugs may eventually prove superior to CB1954; a nitroaryl phosphoramide mustard prodrug activated by NTR shows a greater therapeutic index than CB1954 in a human ovarian carcinoma. 6. The crystal structure of NTR provided the basis for site-directed mutagenesis, which has identified a number of mutants with improved kinetics of CB1954 activation. These can provide improved cell sensitization to CB1954. Combinations of these are being tested. 7. The basis for a positive selection for improved NTR variants has been demonstrated.
引用
收藏
页码:811 / 816
页数:6
相关论文
共 50 条
  • [31] Noninvasive optical imaging of nitroreductase gene-directed enzyme prodrug therapy system in living animals
    S Bhaumik
    T V Sekar
    J Depuy
    J Klimash
    R Paulmurugan
    Gene Therapy, 2012, 19 : 295 - 302
  • [32] Enzyme prodrug therapy of cancer
    Blakey, D
    EXPERT OPINION ON THERAPEUTIC PATENTS, 1997, 7 (09) : 965 - 977
  • [33] The choice of prodrugs for gene directed enzyme prodrug therapy of cancer
    Connors, TA
    GENE THERAPY, 1995, 2 (10) : 702 - 709
  • [34] Quantitative evaluation and comparison of two prodrug-activating suicide gene therapies on oral squamous cell carcinoma
    Xu, Naining
    Tian, Honglei
    Fung, Chun Po
    Lin, Yuntao
    Zhu, Guang
    Shen, Yuehong
    Yang, Hongyu
    AMERICAN JOURNAL OF CANCER RESEARCH, 2021, 11 (04): : 1672 - +
  • [35] Colloidal Gold Modified with a Genetically Engineered Nitroreductase: Toward a Novel Enzyme Delivery System for Cancer Prodrug Therapy
    Gwenin, Vanessa V.
    Gwenin, Chris D.
    Kalaji, Maher
    LANGMUIR, 2011, 27 (23) : 14300 - 14307
  • [36] Synthesis and evaluation of nitroheterocyclic carbamate prodrugs for use with nitroreductase-mediated gene-directed enzyme prodrug therapy
    Hay, MP
    Anderson, RF
    Ferry, DM
    Wilson, WR
    Denny, WA
    JOURNAL OF MEDICINAL CHEMISTRY, 2003, 46 (25) : 5533 - 5545
  • [37] Strategies for enzyme/prodrug cancer therapy
    Xu, G
    McLeod, HL
    CLINICAL CANCER RESEARCH, 2001, 7 (11) : 3314 - 3324
  • [38] Genetic prodrug activating therapy (GPAT) for cancer
    Sikora, K
    CANCER GENE THERAPY, 1997, 4 (01) : 69 - 69
  • [39] Inhibition of human oral squamous cell carcinoma proliferation and migration by prodrug-activating suicide gene therapies
    Xu, Naining
    Tian, Honglei
    Fung, Chun Po
    Lin, Yuntao
    Chen, Yuling
    Zhu, Guang
    Shen, Yuehong
    Guo, Chuanbin
    Yang, Hongyu
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2023, 25 (02)
  • [40] Prodrug cancer gene therapy
    Altaner, Cestmir
    CANCER LETTERS, 2008, 270 (02) : 191 - 201